Clinical Trials List
Protocol NumberCC-220-DLBCL-001
Active
2021-08-01 - 2029-02-28
Phase I
Recruiting3
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Ching Yun Hsieh Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- Yu-Min Liao Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- 王秀慈 Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- Ming-Hung Tsai Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Wei-Ching Lin Division of Radiology
- 陳珈妤 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chieh-Lin Teng Division of Hematology & Oncology
- ZHENG-WEI ZHOU Division of Hematology & Oncology
- YU-HSUAN SHIH Division of Hematology & Oncology
- PO-WEI LIAO Division of Hematology & Oncology
- Tsung -Chih Chen Division of Hematology & Oncology
- HSIN-CHEN LIN Division of Hematology & Oncology
- CHENG-HSIEN LIN Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HSIN-AN HOU Division of General Internal Medicine
- CHENG-HONG TSAI Division of General Internal Medicine
- 劉高郎 Division of Radiology
- Wen-Chien Chou Division of General Internal Medicine
- Chieh-Lung Cheng Division of General Internal Medicine
- WEI-LI MA Division of Hematology & Oncology
- 柯紀綸 Division of Nuclear Medicine
- MING YAO Division of General Internal Medicine
- Chien-Chin Lin Division of General Internal Medicine
- 田豐銘 Division of General Internal Medicine
- SHAN-CHI YU Division of Others -
- - - Division of General Internal Medicine
- Huai-Hsuan Huang Division of General Internal Medicine
- KUAN-YIN KO Division of Nuclear Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
164-224 participants
